On-Demand Broadcast: BTK Inhibition for Adults with CLL or SLL: An Overview of MOA, Clinical Data, and Dosing Considerations

In this broadcast, Alexey V. Danilov, MD, PhD and Herbert Eradat MD, MS explore data on a novel second-generation BTK inhibitor for adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). To obtain expert perspective on the use of a BTK inhibitor and the clinically relevant aspects and its pharmacokinetic (PK)/pharmacodynamic (PD) profile, watch the on-demand broadcast, visit https://bit.ly/3RdN9d4.

1023-BRU-PRC-126 10/2023